Aclarion Inc Stock Price, News & Analysis

Aclarion, Inc. (Nasdaq: ACON) has received a Notice of Allowance for its US Patent Application 16/224,590, enhancing its patent portfolio to 22 U.S. patents. This patent allows Aclarion to utilize Magnetic Resonance Spectroscopy (MRS) to identify Propionic Acid, a biomarker linked to bacterial infections in intervertebral discs. The Nociscan platform aids physicians in distinguishing between painful and nonpainful discs, potentially reducing unnecessary surgeries. CEO Brent Ness emphasized the importance of this advancement in supporting optimal treatment decisions for chronic low back pain.

Aclarion, Inc. (NASDAQ:ACON, ACONW), a healthcare technology company, presented at the 15th annual LD Micro Main Event on October 25, 2022. Executive Chairman Jeff Thramann delivered a company overview and business update. Aclarion focuses on chronic low back pain through its Nociscan platform, utilizing biomarkers and augmented intelligence to aid physicians in identifying pain sources in the lumbar spine. An updated investor presentation is available on their website, enhancing investor communications.

Aclarion, a healthcare technology company, has announced that Dr. Sigurd Berven will join as a key opinion leader to enhance the company's efforts in chronic low back pain diagnosis. Aclarion's Nociscan platform uniquely identifies painful discs using biomarkers and augmented intelligence. This technology aims to improve diagnostic accuracy and treatment strategies. Recently included in a NIH-funded trial, Nociscan further establishes its significance in the spine industry. Aclarion's focus is on robust clinical evidence and payer engagement to drive the adoption of its innovative solutions.

Aclarion announced its participation in the 37th Annual Meeting of the North American Spine Society (NASS), focusing on chronic low back pain (CLBP). The company's Nociscan platform, the first evidence-supported SaaS solution, assists in objectively analyzing intradiscal pain by utilizing biomarkers. Its role in the NIH HEAL Initiative highlights its significance in providing personalized pain assessment. Approximately 266 million people globally suffer from degenerative spine issues, making CLBP a critical healthcare concern.

Aclarion has appointed Dr. John Keller, Chief of Neurosurgery at University of Michigan Health-West, as a Key Opinion Leader in its strategy to enhance clinical evidence for its Nociscan solution, aimed at diagnosing chronic low back pain. Nociscan is a SaaS platform designed to distinguish between painful and non-painful lumbar discs using biomarkers and augmented intelligence. The initiative aligns with Aclarion's goal to secure payer community advocacy and expand its clinical utility evidence, including participation in a pivotal NIH-funded trial involving 200 patients.

Aclarion, a healthcare technology company, announced its participation in the Biomarkers for Evaluating Spine Treatments (BEST) Trial, funded by the NIH HEAL Initiative. This trial aims to optimize treatment for chronic low back pain (cLBP) using biomarkers, including Aclarion's proprietary Nociscan. The study will enroll over 800 patients across 12 academic institutions, with 200 receiving advanced biomarker profiling. The NIH HEAL Initiative supports this research to combat the opioid crisis through tailored cLBP treatments.

Aclarion has launched the Economic Value Analysis of Low back pain (EVAL) study to evaluate the financial impact of its Nociscan technology on chronic low back pain (CLBP) treatment. Conducted by the University of California, the study will assess the cost of care for CLBP patients, with initial findings expected in Q4 2022. Promising results indicate 87% of patients treated with Nociscan show significant improvements at two-year follow-ups, potentially influencing insurance coverage decisions. The study aims to demonstrate Nociscan's economic value, addressing the $134B annual cost of low back pain in the U.S.

Aclarion Inc. (NASDAQ: ACON, ACONW) announced promising two-year results from its pivotal clinical trial on Nociscan, showing that 87% of patients treated for chronic discogenic low back pain reported significant clinical improvement. Results will be discussed at the Annual State of Spine Surgery Think Tank in Mexico, along with a plan for future clinical studies. Aclarion aims to position Nociscan as the standard of care, leveraging its technology to distinguish painful discs and improve cost-effectiveness in treatment. Initial economic analysis results are expected in Q4 2022.

Aclarion, Inc. has successfully closed its initial public offering (IPO), raising approximately $9.4 million through the sale of 2,165,000 shares of common stock and accompanying warrants at a price of $4.35 per share. The IPO began trading on April 22, 2022, under the symbols ACON and ACONW. Maxim Group LLC served as the sole book-running manager and has exercised an option to purchase an additional 324,750 warrants. Aclarion focuses on using Magnetic Resonance Spectroscopy and AI to enhance treatments for the $134.5 billion U.S. low back and neck pain market.